Aberdeen Group plc Has $106.97 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Aberdeen Group plc reduced its position in Regeneron Pharmaceuticals by 16.9%, now holding approximately 203,750 shares valued at $106.97 million.
• Regeneron Pharmaceuticals reported $12.89 EPS for the last quarter, exceeding expectations of $8.43, while also achieving a revenue of $3.68 billion, above the estimated $3.30 billion.
• The company declared a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6% and a payout ratio of 8.87%.

Aberdeen Group plc reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 203,750 shares of the biopharmaceutical company's stock after selling 41,447 shares during the period. Aberdeen Group plc owned approximately 0.19% of Regeneron Pharmaceuticals worth $106,969,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV increased its stake in Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares during the period. Private Trust Co. NA increased its stake in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 19 shares during the period. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 19 shares during the period. Finally, Cove Private Wealth LLC increased its stake in Regeneron Pharmaceuticals by 4.5% during the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 20 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Sanford C. Bernstein raised their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Weiss Ratings restated a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Finally, Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $817.46.

Regeneron Pharmaceuticals Trading Down 0.9%

Shares of REGN opened at $564.63 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The business's fifty day moving average is $573.95 and its 200-day moving average is $565.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market cap of $59.85 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 1.82 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company posted $11.56 EPS. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.